Endometrial stromal sarcoma of the uterus presenting as pulmonary metastasis

Binesh, Fariba; Zahir, Shokouh Taghipour; Akhavan, Ali; Bovanlu, Taghi Roshan

doi:10.1136/bcr-2013-008565

Cited by 5 publications

(2 citation statements)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Magnetic Resonance Cholangiopanc-reatography (MRCP) and Computed Tomography (CT) on the gallbladder sarcomatoid carcinoma ( Supplementary Figure S1 ) demonstrated interruption of extrahepatic bile duct structure and gallbladder wall thickening, suggesting that the patient might have malignant lesions. The immunohistochemistry staining of the tumor specimens showed pan-cytokeratin (pan-CK) (+), Ki67 (+), Heppar-1 (−), CAM5.2 (+), Vimetin (+), CK19 (−), and SMA (+) ( Supplementary Figure S2 ), which are associated with the clinical characteristics of sarcoma patients [ 35 – 38 ].…”

Section: Resultsmentioning

confidence: 99%

Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing

et al. 2016

View full text Add to dashboard Cite

PurposeGallbladder sarcomatoid carcinoma is a rare cancer with no clinical standard treatment. With the rapid development of next generation sequencing, it has been able to provide reasonable treatment options for patients based on genetic variations. However, most cancer drugs are not approval for gallbladder sarcomatoid carcinoma indications. The correlation between drug response and a genetic variation needs to be further elucidated.Experimental DesignThree patient-derived cells-JXQ-3D-001, JXQ-3D-002, and JXQ-3D-003, were derived from biopsy samples of one gallbladder sarcomatoid carcinoma patient with progression and have been characterized. In order to study the relationship between drug sensitivity and gene alteration, genetic mutations of three patient-derived cells were discovered by whole exome sequencing, and drug screening has been performed based on the gene alterations and related signaling pathways that are associated with drug targets.ResultsIt has been found that there are differences in biological characteristics such as morphology, cell proliferation, cell migration and colony formation activity among these three patient-derived cells although they are derived from the same patient. Their sensitivities to the chemotherapy drugs-Fluorouracil, Doxorubicin, and Cisplatin are distinct. Moreover, none of common chemotherapy drugs could inhibit the proliferations of all three patient-derived cells. Comprehensive analysis of their whole exome sequencing demonstrated that tumor-associated genes TP53, AKT2, FGFR3, FGF10, SDHA, and PI3KCA were mutated or amplified. Part of these alterations are actionable. By screening a set of compounds that are associated with the genetic alteration, it has been found that GDC-0941 and PF-04691502 for PI3K-AKT-mTOR pathway inhibitors could dramatically decrease the proliferation of three patient-derived cells. Importantly, expression of phosphorylated AKT and phosphorylated S6 were markedly decreased after treatments with PI3K-AKT-mTOR pathway inhibitors GDC-0941 (0.5 μM) and PF-04691502 (0.1 μM) in all three patient-derived cells. These data suggested that inhibition of the PI3K-AKT-mTOR pathway that was activated by PIK3CA amplification in all three patient-derived cells could reduce the cell proliferation.ConclusionsA patient-derived cell model combined with whole exome sequencing is a powerful tool to elucidate relationship between drug sensitivities and genetic alternations. In these gallbladder sarcomatoid carcinoma patient-derived cells, it is found that PIK3CA amplification could be used as a biomarker to indicate PI3K-AKT-mTOR pathway activation. Block of the pathway may benefit the gallbladder sarcomatoid carcinoma patient with this alternation in hypothesis. The real efficacy needs to be confirmed in vivo or in a clinical trial.

show abstract

Section: Resultsmentioning

confidence: 99%

Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Pulmonary metastasis is a common occurrence in cases of metastatic carcinoma. In relation to gynecologic tumors, the lungs are reported to be the most frequent site of metastasis from lowgrade endometrial stromal sarcoma (36)(37)(38), although this is uncommon (35). However, recent reports indicate that lung metastasis is the most common distant organ metastasis in endometrial tumors (39)(40)(41), with carcinosarcoma having a significantly higher rate of lung metastasis compared to other histological types, and undifferentiated tumors had the highest rate of lung metastasis when considering tumor grade (29).…”

Section: Discussionmentioning

confidence: 99%

Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review

Wang,

Li,

Han

2023

Front. Oncol.

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common malignant tumor of the female reproductive system, and the majority of ECs are low histological grade and confined to the uterus, resulting in a good prognosis. However, metastasis to the lung from a low-grade and early-stage endometrial endometrioid carcinoma (EEC) is extremely rare. Therefore, it is crucial to accurately differentiate between primary pulmonary malignancy and extra-thoracic malignancy presenting as metastatic disease, and flexible bronchoscopy with tissue acquisition plays a key role in this process. Despite its importance, there is limited literature available on the cytology of metastatic endometrial carcinoma in liquid-based cytology of bronchial brush (BB). In this article, we present two rare cases of lung metastasis from low-grade and early-stage EEC, along with a detailed analysis of the cytologic features observed in BB samples. These cases highlight the significance of cytological and histological pathology, complemented by immunohistochemistry (ICH) analysis, in the diagnosis and management of EEC patients. Pathologists should pay close attention to these aspects, while gynecologists need to be mindful of the follow-up and management of early-stage, low-grade EEC patients. By focusing on these areas, healthcare professionals can effectively contribute to the improved care and outcomes of patients with EEC.

show abstract

Low-grade endometrial stromal sarcoma presenting as multiple pulmonary nodules: A potential pitfall in fine needle aspiration and core biopsy specimens - A Cytological - Pathological Correlation

Ronen

Narula

Koizumi

et al. 2018

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Endometrial stromal sarcoma of the uterus presenting as pulmonary metastasis

Cited by 5 publications

References 15 publications

Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing

Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing

Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review

Low-grade endometrial stromal sarcoma presenting as multiple pulmonary nodules: A potential pitfall in fine needle aspiration and core biopsy specimens - A Cytological - Pathological Correlation

Contact Info

Product

Resources

About